BTS statement on malignant mesothelioma in the UK, 2007.
机构信息
Wexham Park Hospital, Slough, UK.
出版信息
Thorax. 2007 Nov;62 Suppl 2(Suppl 2):ii1-ii19. doi: 10.1136/thx.2007.087619.
Abstract
摘要
相似文献
1
BTS statement on malignant mesothelioma in the UK, 2007.
Thorax. 2007 Nov;62 Suppl 2(Suppl 2):ii1-ii19. doi: 10.1136/thx.2007.087619.
2
Statement on malignant mesothelioma in the United Kingdom.
Thorax. 2001 Apr;56(4):250-65. doi: 10.1136/thorax.56.4.250.
3
Multimodality therapy for malignant mesothelioma based on a study of natural history.
Am J Med. 1980 Mar;68(3):356-62. doi: 10.1016/0002-9343(80)90103-5.
4
Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death.
Br J Ind Med. 1988 Mar;45(3):182-7. doi: 10.1136/oem.45.3.182.
5
Mesothelioma.
Br J Hosp Med. 1983 Jun;29(6):521-530, 535-6.
6
Advances in malignant mesothelioma.
N Engl J Med. 2005 Oct 13;353(15):1591-603. doi: 10.1056/NEJMra050152.
7
[Malignant pleural mesothelioma].
Ugeskr Laeger. 2018 Apr 9;180(15).
8
Compensable asbestos-related disease in New South Wales.
Med J Aust. 1983 Sep 3;2(5):221-4. doi: 10.5694/j.1326-5377.1983.tb122428.x.
9
A case from India of pleural malignant mesothelioma probably due to domestic and environmental asbestos exposure: a posthumous report.
BMJ Case Rep. 2019 Mar 31;12(3):e227882. doi: 10.1136/bcr-2018-227882.
10
Death certificate categorization of malignant pleural and peritoneal mesothelioma in a cohort of asbestos insulation workers.
J Soc Occup Med. 1991 Autumn;41(3):137-9. doi: 10.1093/occmed/41.3.137.
引用本文的文献
1
Retrospective analysis of the sensitivity of reporting of thoracic computed tomography for pleural malignancy: an Australian multi-centre study.
J Thorac Dis. 2025 Apr 30;17(4):1958-1966. doi: 10.21037/jtd-24-1797. Epub 2025 Apr 28.
2
Dual implication of endothelial adhesion molecules in tumor progression and cancer immunity.
Cell Adh Migr. 2025 Dec;19(1):2472308. doi: 10.1080/19336918.2025.2472308. Epub 2025 Mar 12.
3
Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?
Curr Oncol. 2024 Aug 27;31(9):4968-4983. doi: 10.3390/curroncol31090368.
4
Update in the Treatment of Pleural Tumors: Robotic Surgery Combined with Hyperthermic Intrathoracic Chemotherapy.
Cancers (Basel). 2024 Apr 26;16(9):1691. doi: 10.3390/cancers16091691.
5
The lncRNAs Gas5, MALAT1 and SNHG8 as diagnostic biomarkers for epithelial malignant pleural mesothelioma in Egyptian patients.
Sci Rep. 2024 Feb 27;14(1):4823. doi: 10.1038/s41598-024-55083-9.
6
Does previous asbestos exposure increase the risk of a post coronary artery bypass graft (CABG) pleural effusion - a routine data study?
BMC Pulm Med. 2023 Aug 21;23(1):307. doi: 10.1186/s12890-023-02555-9.
7
Survival analysis and development of a prognostic nomogram for patients with malignant mesothelioma in different anatomic sites.
Front Oncol. 2022 Nov 10;12:950371. doi: 10.3389/fonc.2022.950371. eCollection 2022.
8
Diagnosis of malignant pleural disease: Ultrasound as "a detective probe".
Thorac Cancer. 2023 Jan;14(3):223-230. doi: 10.1111/1759-7714.14735. Epub 2022 Nov 22.
9
Marital status as an independent prognostic factor for patients of malignant pleural mesothelioma.
Front Med (Lausanne). 2022 Oct 21;9:955619. doi: 10.3389/fmed.2022.955619. eCollection 2022.
10
Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.
Front Oncol. 2022 Jun 17;12:916839. doi: 10.3389/fonc.2022.916839. eCollection 2022.
本文引用的文献
1
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
J Clin Oncol. 2012 Jul 10;30(20):2509-15. doi: 10.1200/JCO.2011.41.5869. Epub 2012 Jun 4.
2
The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
J Thorac Oncol. 2006 Jul;1(6):591-601.
3
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.
Clin Cancer Res. 2006 Dec 1;12(23):7126-31. doi: 10.1158/1078-0432.CCR-06-1101.
4
Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion.
Eur Respir J. 2006 Aug;28(2):409-22. doi: 10.1183/09031936.06.00013706.
5
Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.
J Thorac Imaging. 2006 May;21(2):146-53. doi: 10.1097/00005382-200605000-00006.
6
Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients.
Surg Endosc. 2006 Jun;20(6):919-23. doi: 10.1007/s00464-005-0534-6. Epub 2006 May 2.
7
The undiagnosed pleural effusion.
Clin Chest Med. 2006 Jun;27(2):309-19. doi: 10.1016/j.ccm.2005.12.002.
8
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J Thorac Cardiovasc Surg. 2006 May;131(5):981-7. doi: 10.1016/j.jtcvs.2005.11.044.
9
The evidence on the effectiveness of management for malignant pleural effusion: a systematic review.
Eur J Cardiothorac Surg. 2006 May;29(5):829-38. doi: 10.1016/j.ejcts.2005.12.025. Epub 2006 Apr 12.
10
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
J Clin Oncol. 2006 Mar 20;24(9):1443-8. doi: 10.1200/JCO.2005.04.3190.
Zotero 插件